Alto Neuroscience (ANRO) Competitors

Alto Neuroscience (NYSE:ANRO) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Which has preferable earnings & valuation, ANRO or CADL?

Alto Neuroscience has higher earnings, but lower revenue than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$36.31M	-$2.34	-1.05
Candel Therapeutics	$120K	2,237.93	-$37.94M	-$1.34	-4.00

Does the MarketBeat Community favor ANRO or CADL?

Candel Therapeutics received 1 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 80.00% of users gave Alto Neuroscience an outperform vote while only 65.38% of users gave Candel Therapeutics an outperform vote.

Company	Underperform	Outperform
Alto Neuroscience	Outperform Votes 16 80.00%	Underperform Votes 4 20.00%
Candel Therapeutics	Outperform Votes 17 65.38%	Underperform Votes 9 34.62%

Do institutionals and insiders hold more shares of ANRO or CADL?

13.9% of Candel Therapeutics shares are held by institutional investors. 11.1% of Alto Neuroscience shares are held by company insiders. Comparatively, 16.6% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has more volatility & risk, ANRO or CADL?

Alto Neuroscience has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.87, suggesting that its share price is 187% less volatile than the S&P 500.

Is ANRO or CADL more profitable?

Alto Neuroscience's return on equity of -49.28% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-49.28%	-33.52%
Candel Therapeutics	N/A	-629.29%	-173.39%

Do analysts rate ANRO or CADL?

Alto Neuroscience presently has a consensus target price of $15.40, indicating a potential upside of 528.57%. Candel Therapeutics has a consensus target price of $21.00, indicating a potential upside of 291.79%. Given Alto Neuroscience's higher possible upside, equities analysts clearly believe Alto Neuroscience is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Candel Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to ANRO or CADL?

In the previous week, Candel Therapeutics had 3 more articles in the media than Alto Neuroscience. MarketBeat recorded 4 mentions for Candel Therapeutics and 1 mentions for Alto Neuroscience. Candel Therapeutics' average media sentiment score of 1.31 beat Alto Neuroscience's score of 0.54 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Candel Therapeutics beats Alto Neuroscience on 8 of the 15 factors compared between the two stocks.